This site is intended for healthcare professionals

Complete Response Letter for Pedmark for the prevention of ototoxicity associated with cisplatin chemotherapy in pediatric patients with localized, non-metastatic, solid tumors. Fennec Pharma

Read time: 1 mins
Last updated:16th Mar 2021
Published:13th Aug 2020
Condition: Cisplatin-induced Hearing Loss
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest